CAJ | 학술논문

目的：探讨阿托伐他汀干预下CRP 1059 G/C基因多态性对脑梗死（ CI ）人群的影响。方法采用多聚酶链式反应-限制性片段长度多态性（PCR-RFLP）测定123例CI患者及97例同期门诊健康体检者CRP 1059G/C基因型和等位基因；应用免疫透射比浊法测定CRP 水平。 CI患者给予阿托伐他汀20mg· d-1口服，并于3个月后复查血清CRP 和血脂水平。结果阿托伐他汀干预下， CRP 1059 G/G、G/C基因型对CRP水平差异无统计学意义（ P＞0．05）。阿托伐他汀治疗显著降低 CI 患者血清 CRP 及LDL-C 水平（均P＜0．05），但二者下降程度无关联（P＞0．05）。 CI患者NIHSS评分为重度组CRP水平明显高于轻、中度患者（P＜0．05），但CI患者NIHSS评分与基因型及等位基因无关联（P＞0．05）。结论阿托伐他汀干预下CRP 1059G/C基因多态性与脑梗死人群血清CRP水平下降无关联。阿托伐他汀可显著降低脑梗死人群血清CRP水平及LDL-C水平，但二者下降水平可能无关联。
목적：탐토아탁벌타정간예하CRP 1059 G/C기인다태성대뇌경사（ CI ）인군적영향。방법채용다취매련식반응-한제성편단장도다태성（PCR-RFLP）측정123례CI환자급97례동기문진건강체검자CRP 1059G/C기인형화등위기인；응용면역투사비탁법측정CRP 수평。 CI환자급여아탁벌타정20mg· d-1구복，병우3개월후복사혈청CRP 화혈지수평。결과아탁벌타정간예하， CRP 1059 G/G、G/C기인형대CRP수평차이무통계학의의（ P＞0．05）。아탁벌타정치료현저강저 CI 환자혈청 CRP 급LDL-C 수평（균P＜0．05），단이자하강정도무관련（P＞0．05）。 CI환자NIHSS평분위중도조CRP수평명현고우경、중도환자（P＜0．05），단CI환자NIHSS평분여기인형급등위기인무관련（P＞0．05）。결론아탁벌타정간예하CRP 1059G/C기인다태성여뇌경사인군혈청CRP수평하강무관련。아탁벌타정가현저강저뇌경사인군혈청CRP수평급LDL-C수평，단이자하강수평가능무관련。
Objective To explore the effective of CRP 1059 G/C gene polymorphism on the cerebralinfarction(CI) population with atorvastatin.Methods The CRP 1059G/C genotype and allele frequencies wereasseyed by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) measured 123 patientswith CI and 97 controls.CRP levels was detected by immune turbidimetric.CI patients given atorvastatin 20mg· d-1orally, and reviewed the serum CRP and LDL-C levels follow-up 3 months .Results There were no signficantdifference of the decline on serum CRP levels between CRP 1059G/G and G/C genotype with atorvastatin (P>0.05).Atorvastatin significantly reduced the serum CRP and LDL -C levels in patients with CI( P <0.05).Although, therewere no significant correlation of the decline in serum levels of CRP and LDL -C with atorvastatin(P>0.05).The CRPlevels with stroke rating for NIHSS was higher than the others (P <0.05).Even through,there were no statisticaldifferences that neither CRP genotype or alleles showed an association with patient’ s condition ( P >0.05 ). Conclusions There is no connection between the alleles of CRP 1059G/C and serum CRP levels with atorvastatin.Within atorvastatin treatment,serum CRP and LDL-C levels of CI population are significantly decreased ,but thedecline has no significant correlation.